Tapentadol

Generic Name: Tapentadol

Brand Names: Nucynta

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₃NO

CAS Number: 175591-23-8

Unique Ingredient Identifier: H8A007M585

Background: Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.
...

Indication: 用于治疗严重到需要阿片类镇痛剂且替代治疗不充分的急性疼痛。

Associated Conditions: Diabetic Peripheral Neuropathic Pain (DPN), Severe Acute Pain, Severe Pain

Associated Therapies: -

Clinical Trials

Tapentadol vs Tramadol in Total Knee Arthroplasty

Phase 4

Recruiting

Conditions: Total Knee Replacement
Post-operative Pain
Chronic Pain

Interventions: Drug: Tramadol
Drug: Tapentadol

First Posted Date: 2024-02-21

Last Posted Date: 2024-05-14

Lead Sponsor: University of Thessaly

Target Recruit Count: 96

Registration Number: NCT06269770

Locations: 🇬🇷
University Hospital Of Larissa, Larissa, Thessaly, Greece

Effects of Tapentadol Versus Oxycodone After Hysterectomy.

Phase 4

Completed

Conditions: Pain, Postoperative
Pain Uterus
Pain, Acute
Opioid Use
Analgesics, Antipyretics, and Antirheumatics Causing Adverse Effects in Therapeutic Use
Visceral Pain

Interventions: Drug: Tapentadol
Drug: Oxycodone

First Posted Date: 2017-10-19

Last Posted Date: 2019-04-04

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 86

Registration Number: NCT03314792

Locations: 🇳🇴
Oslo University Hospital, Oslo, Norway

Depot-opioids for Pre- and Postoperative Pain Relief After Primary Knee Arthroplasty.Tapentadol vs Oxycodone vs Placebo

Phase 3

Completed

Conditions: Joint Diseases

Interventions: Drug: Tapentadol
Drug: Oxycodone
Drug: Placebo
Drug: usual pain treatment

First Posted Date: 2015-11-13

Last Posted Date: 2021-11-16

Lead Sponsor: St. Olavs Hospital

Target Recruit Count: 134

Registration Number: NCT02604446

Locations: 🇳🇴
Anestesiavdelingen, St Olavs Hospital, Trondheim, Norway

Use of Tapentadol Oral Solution for Pain After Surgery in Children From Newborn to Less Than 2 Years Old

Phase 2

Terminated

Conditions: Moderate to Severe Acute Postoperative Pain

Interventions: Drug: Tapentadol

First Posted Date: 2014-08-20

Last Posted Date: 2018-01-29

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 40

Registration Number: NCT02221674

Locations: 🇵🇱
PL001, Łódź, Poland
🇺🇸
US004, Philadelphia, Pennsylvania, United States
🇺🇸
US001, Palo Alto, California, United States

and more 4 locations

Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain

Completed

Conditions: Neuropathic Pain
Tumor
Breakthrough Cancer Pain
Cancer Pain

Interventions: Drug: Morphine
Drug: Fentanyl
Drug: Methadone
Drug: Buprenorphine
Drug: Oxycodone
Drug: Hydromorphone
Drug: Tapentadol

First Posted Date: 2013-09-19

Last Posted Date: 2016-04-14

Lead Sponsor: Mario Negri Institute for Pharmacological Research

Target Recruit Count: 150

Registration Number: NCT01946555

Locations: 🇮🇹
A.O. Universitaria Parma, Parma, Italia, Italy
🇮🇹
Ospedale di Piacenza, Piacenza, Italy
🇮🇹
Ospedale Magati, Scandiano, Italia, Italy

and more 8 locations

Phase 1 Pharmacokinetic Study of Tapentadol Prolonged-Release 250 Milligram (mg) Formulation in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tapentadol

First Posted Date: 2013-06-13

Last Posted Date: 2013-06-13

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Target Recruit Count: 18

Registration Number: NCT01877226

Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain

Phase 2

Completed

Conditions: Postoperative Pain
Acute Pain

Interventions: Drug: Tapentadol

First Posted Date: 2012-11-20

Last Posted Date: 2019-11-04

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 86

Registration Number: NCT01729728

Locations: 🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States

Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.

Phase 2

Completed

Conditions: Low Back Pain

Interventions: Drug: High Dose GRT6005
Drug: Tapentadol
Drug: Low Dose GRT6005
Drug: Medium Dose GRT6005
Drug: Matching Placebo

First Posted Date: 2012-11-12

Last Posted Date: 2021-07-15

Lead Sponsor: Tris Pharma, Inc.

Target Recruit Count: 1089

Registration Number: NCT01725087

Locations: 🇫🇮
FI005, Kokkola, Finland
🇦🇹
AT001, Wien, Austria
🇦🇹
AT005, Wien, Austria

and more 76 locations

Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans

Phase 4

Completed

Conditions: Effects of 2 Mu-opiates on Gastrointestinal Transit

Interventions: Drug: Oxycodone
Drug: Placebo
Drug: Tapentadol

First Posted Date: 2011-12-28

Last Posted Date: 2012-12-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 38

Registration Number: NCT01500317

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Intravenous Tapentadol in Post-Bunionectomy Pain

Phase 2

Completed

Conditions: Bunion
Pain

Interventions: Drug: Matching Placebo
Drug: Tapentadol

First Posted Date: 2011-09-16

Last Posted Date: 2019-10-28

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 177

Registration Number: NCT01435577

Locations: 🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy